Cover Image
Market Research Report

MOLECULAR DIAGNOSTICS FOR CANCER. MARKETS, STRATEGIES AND TRENDS. FORECASTS BY CANCER TYPE AND BY COUNTRY. WITH EXECUTIVE AND CONSULTANT GUIDES. 2019 TO 2023

Published by Howe Sound Research Product code 350277
Published Content info 262 Pages
Delivery time: 1-2 business days
Price
Back to Top
MOLECULAR DIAGNOSTICS FOR CANCER. MARKETS, STRATEGIES AND TRENDS. FORECASTS BY CANCER TYPE AND BY COUNTRY. WITH EXECUTIVE AND CONSULTANT GUIDES. 2019 TO 2023
Published: March 5, 2019 Content info: 262 Pages
Description

OVERVIEW:

A market that just keeps on growing. Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge. Learn all about it in this new report from Howe Sound Research. A range of dynamic trends are pushing market growth and company valuations. Trends like ......

  • personalized medicine
  • pharmacogenomics
  • liquid biopsy
  • emergence of new economies with large markets
  • greater understanding of the role of genetic material in Disease and Health

Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage.

In addition customization work, breakouts for particular segments, assistance and support is included free of charge with every report.

"Molecular Diagnostics Cancer Oncology - Global Market Size, Strategy and Forecasts - 2019 to 2023" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2018 United States Medicare Fee Payment Schedules to help understand test pricing in detail. See lists of all current FDA Approved Molecular Diagnostic Tests. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Based on extensive primary and secondary research the testing volume data is broken down into price and volumes allowing researchers and investors to quickly create informed and reasonable forecasts of demand. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School
Table of Contents

Table of Contents

  • i. Molecular Diagnostics Oncology Market - Strategic Situation Analysis
  • ii. Guide for Executives, Marketing, Sales and Business Development Staff
  • iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1. What is Molecular Diagnostics
  • 1.2. The Diagnostics Revolution
  • 1.3. Market Definition
    • 1.3.1. Revenue Market Size
  • 1.4. Methodology
    • 1.4.1. Authors
    • 1.4.2. Sources
  • 1.5. U.S. Medical Market and laboratory Testing - Perspective
    • 1.5.1. U.S. Medicare Expenditures for Laboratory Testing

2. Market Overview

  • 2.1. Market Participants
  • 2.2. Market Segments
    • 2.2.1. Traditional Market Segmentation
    • 2.2.2. Laboratory Focus and Segmentation
  • 2.3. Industry Structure
    • 2.3.1. Hospital Testing Share
    • 2.3.2. Economies of Scale
    • 2.3.3. Physician Office Lab's
    • 2.3.4. Physician's and POCT
  • 2.4. Profiles of Key MDx Companies
    • 10X Genomics
    • Abbott Laboratories
    • Adaptive Biotechnologies
    • Aethlon Medical
    • Agena Bioscience
    • Angle plc
    • Apocell
    • ARUP Laboratories
    • Beckman Coulter
    • Becton Dickinson
    • Bioarray Genetics
    • BioCartis
    • Biocept
    • Biodesix Inc.
    • BioFluidica
    • BioGenex
    • bioMérieux
    • Bio-Rad
    • Bio-Techne
    • Bristol-Myers Squibb
    • Cancer Genetics
    • Caris Molecular Diagnostics
    • CellMax Life
    • Charles River
    • Chronix Biomedical
    • Circulogene
    • Clearbridge BioMedics
    • Clinical Genomics
    • Cynvenio
    • Cytolumina Technologies Corp.
    • CytoTrack
    • Dako (Agilent)
    • Diagnologix LLC
    • Epic Sciences
    • Exosome Diagnostics
    • Fluidigm Corp
    • Fluxion Biosciences
    • Foundation Medicine
    • Freenome
    • Genomic Health
    • GenomOncology
    • GRAIL
    • Guardant Health
    • HalioDx
    • Horizon Discovery
    • HTG Molecular Diagnostics
    • iCellate
    • Illumina
    • Incell Dx
    • Inivata
    • Integrated Diagnostics
    • Invivoscribe
    • Leica Biosystems
    • Luminex
    • MDx Health
    • Merck & Co., Inc
    • MIODx
    • Molecular MD
    • MRM Proteomics Inc
    • Myriad Genetics/Myriad RBM
    • Nanostring
    • Natera
    • Neogenomics
    • New Oncology
    • Oncocyte
    • Ortho Clinical Diagnostics
    • Perkin Elmer
    • Personal Genome Diagnostics
    • Pfizer
    • Promega
    • Protagen Diagnostics
    • Qiagen
    • Quanterix
    • Rarecells SAS
    • Roche Diagnostics
    • Siemens
    • Silicon Biosystems
    • SkylineDx
    • SRI International
    • Sysmex
    • Thermo Fisher
    • Trovagene
    • Vortex Biosciences

3. Market Trends

  • 3.1. Factors Driving Growth
    • 3.1.1. New Diagnostics Create New Markets
    • 3.1.2. New Roles for Diagnostics.
    • 3.1.3. Longevity and Outcomes
    • 3.1.3. Expanding the Pharmaceutical Toolbox.
    • 3.1.4. Regulatory Retreat
  • 3.2. Factors Limiting Growth
    • 3.2.1. Falling Prices
    • 3.2.2. Lower Costs.
    • 3.2.3. Testing as a Controllable Cost.
    • 3.2.4. Wellness has a Downside
  • 3.3. Instrumentation and Automation
    • 3.3.1. Instruments Key to Market Share
    • 3.3.2. Bioinformatics Plays a Role.
  • 3.4. Diagnostic Technology Development
    • 3.4.1. Next Generation Sequencing.
    • 3.4.2. Shifting Role of Diagnostics
    • 3.4.3. Multiplexing and Foundation One
    • 3.4.4. Pharmacogenomics Technology
    • 3.4.5. Whole Genome Sequencing
    • 3.4.6. Gene Editing and Gene Therapy

4. Molecular Diagnostics Recent Developments

  • Recent Developments - Importance and How to Use This Section
    • Importance of These Developments
    • How to Use This Section
  • Icon Acquires MolecularMD
  • Guardant Health to Develop Companion Diagnostic Tests for AstraZeneca
  • Adaptive Biotechnologies to Leverage Genentech, Microsoft Deals to Advance Immune Profiling Business
  • Illumina to Launch New NovaSeq Chip, iSeq Kit; Grow Oncology and Reproductive Health Business
  • UgenTec, MDxHealth Partner To Develop AI Software for Prostate Cancer Tests
  • Guardant Health, Core Diagnostics to Offer Liquid Biopsy in India
  • Invitae Q3 Revenues More Than Double
  • Illumina to Acquire Pacific Biosciences
  • Lung Cancer Panel From PlexBio Receives CE Mark
  • Thermo Fisher Scientific Gets CE-IVD Mark for Oncomine Dx
  • Merck KGaA, ArcherDx Partner to Develop CDx for Downstream Therapeutic
  • Foundation Medicine and Merck to Develop Diagnostic Tests for Keytruda
  • Cancer Genetics and NovellusDx to Merge
  • ApoCell Expands Immuno-Oncology Biomarker Services
  • MRM Proteomics Inc and Exactis Innovation Partner
  • Agilent Companion Diagnostic Gains FDA Approval in Urothelial Carcinoma
  • Fluidigm Partners with GenomOncology to Provide Immuno-Oncology Solution
  • MolecularMD Launches Validated Tumor Mutation Burden Assay
  • Minomic Secures Key Patent in the United States and China
  • Biocartis and Wondfo Announce Joint Venture
  • Five Prime Therapeutics Announces Collaboration with Roche to Develop Companion Diagnostics
  • Biodesix Acquires Integrated Diagnostics
  • Predicine, Kintor Pharmaceuticals Partner on Clinical Trials, CDx
  • Bio-Techne to Acquire Exosome Dx for Up to $575M
  • GRAIL Announces Data on Detection of Early-Stage Lung Cancers
  • CellMax Life, IncellDx Partner to Develop Circulating Tumor Cell Tests
  • Quest to Offer Thermo Fisher's Oncomine Dx Target Test
  • Angle, Abbott Ink Deal for Use of FISH With Harvested CTCs
  • Foundation Medicine to Profile Samples for European Cancer Network
  • GRAIL Details Plans for Early Cancer Detection Trials, Products
  • Avalon GloboCare, Da An Gene Collaborate on Liquid Biopsy Diagnostics
  • OncoDNA Inks Russian Distribution Deal With Genext
  • Biocept Prices $15M Public Offering

5. The Global Market for MDx Cancer

  • 5.1. MDx Cancer - Global Market Overview by Country
    • 5.1.1. Table - Global Market by Country
    • 5.1.2. Chart - Global Market by Country

6. Global MDx Cancer Markets - By Type of Cancer

  • 6.1. Global Market by Cancer Type - Overview
    • 6.1.1. Table - Global Market by Cancer Type
    • 6.1.2. Chart - Global Market by Cancer Type - 2018/2023 Comparison
    • 6.1.3. Chart - Global Market by Cancer Type - 2018
    • 6.1.4. Chart - Global Market by Cancer Type -2023
    • 6.1.4. Chart - Global Market by Cancer Type - Share by Year
  • 6.2. MDx Breast Cancer
    • 6.2.1. Table Breast Cancer Testing - by Country
    • 6.2.2. Chart - Breast Cancer Testing Growth
  • 6.3. MDx Colorectal Cancer
    • 6.3.1. Table Colorectal Cancer Testing - by Country
    • 6.3.2. Chart - Colorectal Cancer Testing Growth
  • 6.4. MDx Cervical Cancer
    • 6.4.1. Table Cervical Cancer Testing - by Country
    • 6.4.2. Chart - Cervical Cancer Testing Growth
  • 6.5. MDx Lung Cancer
    • 6.5.1. Table Lung Cancer Testing - by Country
    • 6.5.2. Chart - Lung Cancer Testing Growth
  • 6.6. MDx Precancer
    • 6.2.1. Table Precancer Testing - by Country
    • 6.6.2. Chart - Precancer Testing Growth
  • 6.7. MDx Prostate Cancer
    • 6.7.1. Table Prostate Cancer Testing - by Country
    • 6.7.2. Chart - Prostate Cancer Testing Growth
  • 6.8. MDx Melanoma
    • 6.8.1. Table Melanoma Testing - by Country
    • 6.8.2. Chart - Melanoma Testing Growth
  • 6.9. MDx Blood Cancer
    • 6.9.1. Table Blood Cancer Testing - by Country
    • 6.9.2. Chart - Blood Cancer Testing Growth
  • 6.10. MDx Other Cancer
    • 6.10.1. Table Other Cancer Testing - by Country
    • 6.10.2. Chart - Other Cancer Testing Growth

7. Cancer Treatment and Trials

  • 7.1. FDA Cancer Drug Approvals by Year
  • 7.2. Clinical Trials Started 2010 to 2016
  • 7.3. Prevalence of Cancer Treatments - 2015

Appendices

  • I. United States Medicare System: January 2018 Clinical Laboratory Fees Schedule - National Limit and Midpoint
  • II. FDA Approved Human Genetic Tests
  • III. FDA Approved Microbial Tests
  • III. FDA Approved Pharmacogenomics Tests

Table of Tables

  • Table 1: Lab Spending 2014 to 2024
  • Table 2: Market Players by Type
  • Table 3: Clinical Laboratory Departments and Segments
  • Table 4: Laboratory Management Focus - Different Approaches
  • Table 5: Key Segmentation Variables Going Forward
  • Table 6: Five Factors Driving Growth
  • Table 7: Four Factors Limiting Growth
  • Table 8: Key Diagnostic Laboratory Technology Trends
  • Table 9: Next Generation Sequencing Technologies - Speed and Cost
  • Table 10: - Global MDx Cancer Market by Region
  • Table 11: Global Market by Cancer Type
  • Table 12: MDx Breast Cancer by Country
  • Table 13: MDx Colorectal Cancer by Country
  • Table 14: Cervical Cancer Testing by Country
  • Table 15: Lung Cancer Testing by Country
  • Table 16: Precancer Testing by Country
  • Table 17: Prostate Cancer Testing by Country
  • Table 18: MDx Melanoma by Country
  • Table 19: MDx Blood Cancer by Country
  • Table 20: MDx Other Cancer Testing by Country
  • Table 21: 2018 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1: Clinical Lab Spending 2014 to 2024
  • Figure 2: Growth in Aging Population
  • Figure 3: Death Rates from Cancer - USA
  • Figure 4: Comparing MDx Diagnostic and Traditional Testing
  • Figure 5: 2018 Global Market Density Chart
  • Figure 6: MDx Market by Cancer - 2018 vs. 2023
  • Figure 7: Cancer Market 2018
  • Figure 8: Cancer Market 2023
  • Figure 9: MDx Cancer Share by Year
  • Figure 10: Breast Cancer Testing Growth
  • Figure 11: Colorectal Cancer Testing Growth
  • Figure 12: Cervical Cancer Testing Growth
  • Figure 13: Lung Cancer Testing Growth
  • Figure 14: Precancer Testing Growth
  • Figure 15: Prostate Cancer Testing Growth
  • Figure 16: Melanoma Testing Growth
  • Figure 17: Blood Cancer Testing Growth
  • Figure 18: Other Cancer Testing Growth
  • Figure 19: FDA Cancer Drug Approvals by Year
  • Figure 20: Clinical Trials for Immunotherapy by Year
  • Figure 21: Pie Chart of Prevalence of Cancer Treatments
Back to Top